Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 18/20 | 0.71 |
| ▸ | PRKAB2 | O43741 | 13/20 | 0.68 |
| ▸ | PRKAG1 | P54619 | 13/20 | 0.68 |
| ▸ | PRKAA1 | Q13131 | 13/20 | 0.68 |
| ▸ | PRKAG3 | Q9UGI9 | 13/20 | 0.68 |
| ▸ | PRKAG2 | Q9UGJ0 | 13/20 | 0.68 |
| ▸ | PRKAB1 | Q9Y478 | 13/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033485 | 0.93 | PRKAA2 (0.66) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL14649065 | 0.91 | PRKAA2 (0.70) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL14652452 | 0.88 | PRKAA2 (0.72) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL63417 | 0.85 | PRKAA2 (0.69) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518922 | 0.84 | PRKAA2 (0.98) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL2508098 | 0.84 | TMEM97 (0.71) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL4341273 | 0.84 | PRKAA2 (0.67) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518208 | 0.83 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL12199890 | 0.83 | PRKAA2 (0.74) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL14649115 | 0.83 | PRKAA2 (0.66) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079769-A | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-12-15 | — | — | CN | claimed |
| US-8871770-B2 | Carboxamide compounds and methods for using the same | MIDCAP FINANCIAL TRUST | 2014-10-28 | — | — | US | claimed |
| US-20140148467-A1 | Carboxamide Compounds and Methods for Using the Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-29 | — | — | US | claimed |
| JP-2011527665-A | — | — | 2011-11-04 | — | — | JP | claimed |
| EP-2276761-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| WO-2009132136-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | claimed |
| CN-112079769-A | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-106928211-B | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-09-08 | — | — | CN | disclosed |
| CN-106928211-A | Benzamide compound for treating dysbolism | 里格尔药品股份有限公司 | 2017-07-07 | — | — | CN | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2276761-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009132136-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | PRKAA2 413/4885PRKAB2 541/4885PRKAG1 860/4885 |
| US-20140148467-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | PRKAA2 3/4885PRKAB2 8/4885PRKAG1 6/4885 |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | PC, AK2, PRKAA2 | PRKAA2 3/4885PRKAB2 8/4885PRKAG1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.